Clinical effect of percutaneous transhepatic cholangial drainage combined with biliary stent implantation in treatment of high malignant obstructive jaundice and the influencing factors for prognosis
-
摘要:
目的探讨经皮肝穿刺胆管引流术(PTCD)联合胆道支架植入术治疗高位恶性梗阻性黄疸(MOJ)的效果及影响生存期的危险因素。方法回顾性分析解放军空军总医院肝胆外科2015年6月-2017年6月收治的92例高位MOJ患者临床资料。符合正态分布的计量资料两组间比较采用t检验,多组间比较采用方差分析,进一步两两比较采用SNK-q检验;非正态分布的计量资料两组间比较采用Mann-Whitney U检验。计数资料组间比较采用χ2检验。采用受试者工作特征曲线(ROC曲线)明确影响生存期指标的最佳截断值,根据最佳截断值进行分组,采用Kaplan-Meier法进行生存分析。多因素Cox风险模型分析明确影响患者生存期的独立危险因素。结果所有患者均获得随访,随访时间1~10个月,中位随访时间6个月。随访期间56例患者死亡,36例患者存活,中位生存期(OS)为6个月,随访末期生存率39. 1%,半年生存率44. 6%。14例患者出现术后并发症,并发症发生率为15. 2%。术后3 d及术后1周的TBil、DBil、ALT、AST复查结果显示,上述指标水平显著下降且差异均有统计学意义(F值分别为206. 264、1...
Abstract:Objective To investigate the clinical effect of percutaneous transhepatic cholangial drainage ( PTCD) combined with biliarystent implantation in the treatment of high malignant obstructive jaundice ( MOJ) and the risk factors for survival time. Methods A retro-spective analysis was performed for the clinical data of 92 patients with high MOJ who were admitted to Department of Hepatobiliary Surgeryin Air Force General Hospital, PLA, from June 2015 to June 2017. The t-test was used for comparison of normally distributed continuousdata between two groups; an analysis of variance was used for comparison between multiple groups, and the SNK-q test was used for furthercomparison between two groups. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data betweentwo groups. The chi-square test was used for comparison of categorical data between groups. The receiver operating characteristic ( ROC) curve was used to determine the optimal cut-off values of influencing factors for survival time; the patients were divided into groups accord-ing to the optimal cut-off values, and the Kaplan-Meier method was used for survival analysis. The multivariate Cox proportional hazardsmodel was used to identify the independent influencing factors for survival time. Results All patients were followed up for a median time of6 months ( range 1-10 months) . A total of 56 patients died and 36 survived during follow-up, with a median survival time of 6 months, asurvival rate of 39. 1% at the end of follow-up, and a half-year survival rate of 44. 6%. Of all 92 patients, 14 experienced postoperativecomplications, resulting in an incidence rate of complications of 15. 2%. At 3 days and 1 week after surgery, there were significant reduc-tions in total bilirubin ( TBil) , direct bilirubin, alanine aminotransferase ( ALT) , and aspartate aminotransferase ( F = 206. 264, 106. 161, 86. 332, and 166. 857, all P < 0. 05) . The ROC Curve was used to analyze the data, TBil had a sensitivity of 95. 12% and a specificity of46. 15% at the optimal cut-off value of 112. 9 μmol/L; ALT had a sensitivity of 92. 68% and a specificity of 31. 58% at the optimal cut-off value of 210 U/L; albumin had a sensitivity of 68. 29% and a specificity of 58. 33% at the optimal cut-off value of 35. 7 g/L; red blood cell count had a sensitivity of 60. 98% and a specificity of 69. 23% at the optimal cut-off value of 3. 56 × 1012/L. Child-Pugh class, TBil, and ALT showed a significant difference in predicting overall survival ( all P < 0. 05) . The multivariate Cox proportional hazards model showed that Child-Pugh class C was an independent influencing factor for survival time after PTCD combined with biliary stent implantation. Conclusion PTCD combined with biliary stent implantation has a good clinical effect in the treatment of patients with MOJ, but preoperative liver function has a great impact on survival time. Therefore, liver function should be observed dynamically to guide clinical treatment, in order to prolong the survival time of such patients.
-
Key words:
- jaundice, obstructive /
- drainage /
- prognosis /
- risk factors
-
[1] XU XJ, LI JJ, WU J, et al. A systematic review and meta-a-nalysis of intraluminal brachytherapy versus stent alone in thetreatment of malignant obstructive jaundice[J]. Cardiovasc In-ter Radiol, 2018, 41 (2) :206-217. [2] MA J, LUO J, GU J, et al. Malignant obstructive jaundicetreated with intraluminal placement of Iodine-125 seedstrands and metal stents:An analysis of long-term outcomesand prognostic features[J]. Brachytherapy, 2018, 17 (4) :689-695. [3] WANG L, YU WF. Obstructive jaundice and perioperative man-agement[J]. Acta Anaesthesiol Taiwan, 2014, 52 (1) :22-29. [4] XU G. Clinical effect of biliary metal stent implantation via en-doscopic retrograde cholangiopancreatography in treatment ofunresectable malignant extrahepatic biliary obstruction[J]. JClin Hepatol, 2018, 34 (2) :337-340. (in Chinese) 徐刚.经内镜逆行胰胆管造影胆道金属支架置入治疗不可切除肝外胆道恶性梗阻的效果观察[J].临床肝胆病杂志, 2018, 34 (2) :337-340. [5] CHEN Y, WANG XL, YAN ZP, et al. The use of125I seed strands forintraluminal brachytherapy of malignant obstructive jaundice[J].Cancer Biother Radiopharm, 2012, 27 (5) :317-323. [6] YAO GL, JIANG Y, ZHAO YX, et al. Comparative efficacy ofpalliative biliary enteric extraction and percutaneous biliarystenting under ultrasound guidance in the treatment of malig-nant obstructive jaundice[J]. J Clin Exp Med, 2018, 22 (17) :2430-2433. (in Chinese) 姚广力, 江怡, 赵云歆, 等.恶性梗阻性黄疸患者经皮经肝胆管引流途径胆道支架置入与姑息性胆肠内引流的疗效比较[J].临床和实验医学杂志, 2018, 22 (17) :2430-2433. [7] CHEN TS, LI SY. Percutaneous transhepatic cholangial drain-age for the comprehensive treatment of malignant biliary ob-struction[J]. Clin J Med Offic, 2017, 45 (9) :881-883. (inChinese) 陈挺松, 李淑英.恶性胆道梗阻经皮肝穿综合治疗[J].临床军医杂志, 2017, 45 (9) :881-883. [8] KIKUYAMA M, SHIRANE N, KAWAGUCHI S, et al. New 14-mm diameter Niti-S biliary uncovered metal stent for unresect-able distal biliary malignant obstruction[J]. World J Gastroint-est Endosc, 2018, 10 (1) :16-22. [9] WANG X, LI XC. Rsearch advances in palliative treatment ofcholangiocarcinoma[J]. J Clin Hepatol, 2016, 32 (5) :1022-1025. (in Chinese) 王荇, 李相成.胆管癌姑息治疗的研究进展[J].临床肝胆病杂志, 2016, 32 (5) :1022-1025. [10] XU C, SHI HB, LIU S, et al. Transhepatic biliary drainage forthe treatment of low position malignant obstructive jaundice:An analysis of related factors influencing the prognosis[J]. JVasc Interv Radiol, 2013, 125 (3) :360-367. [11] CHANG ZK, KOU ZP, LI SX, et al. To evaluate the correlationbetween the change of immune system function before and af-ter the treatment of malignant obstructive type jaundice treatedwith biliary stent[J]. Eur Rev Med Pharmaco, 2018, 22 (6) :1638. [12] TANG K, SUI LL, XU G, et al. Effects of different palliativejaundice reducing methods on immunologic functions in pa-tients with advanced malignant obstructive jaundice[J]. Anti-cancer Res, 2017, 37 (8) :4665-4670. [13] ADANG S, RINO AG, MURDANI A, et al. Changes in tumornekrosis factor alpha and interleukin 6 levels in patients withobstructive jaundice due to pancreatobiliary cancer who under-went biliary drainage[J]. Tijoghade, 2016, 17 (2) :92-98. [14] WANG WJ, YU CH. Improvement in liver function in patientswith malignant obstructive jaundice after endoscopic biliarymetallic stent drainage[J]. J Clin Hepatol, 2015, 31 (8) :1295-1298. (in Chinese) 王文君, 于聪慧.胆道支架引流术对恶性梗阻性黄疸患者肝功能的影响[J].临床肝胆病杂志, 2015, 31 (8) :1295-1298. [15] ZHANG C, YANG YL, WU P, et al. Prevention and treatmentof complications for full-covered self-expanding removablemetal stents in malignant obstructive jaundice[J]. Natl Med JChina, 2015, 95 (6) :416-419. (in Chinese) 张诚, 杨玉龙, 吴萍, 等.全覆膜自膨式可回收金属支架治疗恶性梗阻性黄疸的并发症及防治策略[J].中华医学杂志, 2015, 95 (6) :416-419. [16] DELDEN OMV, LAMERIS JS. Percutaneous drainage and stent-ing for palliation of malignant bile duct obstruction[J]. Eur Radi-ol, 2008, 18 (3) :448-456. [17] INAL M, AKGL E, AKSUNGUR E, et al. Percutaneous self-expandable uncovered metallic stents in malignant biliary ob-struction:Complications, follow-up and reintervention in 154patients[J]. Acta Radiol, 2015, 44 (2) :139-146. [18] ZHANG GY, LI WT, PENG WJ, et al. Clinical outcomes andprediction of survival following percutaneous biliary drainagefor malignant obstructive jaundice[J]. Oncol Lett, 2014, 7 (4) :1185-1190. [19] HYUN H, CHOI SY, KIM KA, et al. Safety and efficacy of per-cutaneous biliary covered stent placement in patients with ma-lignant biliary hilar obstruction; correlation with liver function[J]. Cardiovasc Intervent Radiol, 2016, 39 (9) :1298-1305. 期刊类型引用(30)
1. 汪淑佳,俞黎. 多学科团队诊疗模式下的PDCA循环管理在梗阻性黄疸患者围术期护理中的应用效果分析. 中国社区医师. 2025(02): 96-98 . 百度学术
2. 易衡,何芬,王曦,冯谦,唐杰,卿小琼,孙菲菲,陈重. 超声引导下PTCD治疗晚期MOJ疗效及预后因素分析. 武汉大学学报(医学版). 2024(07): 814-819 . 百度学术
3. 李鸿. 老年晚期恶性梗阻性黄疸患者实时超声弹性成像定量分析对PTCD预后的预测价值. 昆明医科大学学报. 2023(01): 122-127 . 百度学术
4. 李鸿. 老年晚期恶性梗阻性黄疸患者实时超声弹性成像定量分析对PTCD预后的评估价值. 昆明医科大学学报. 2023(02): 150-155 . 百度学术
5. 梁亚丽,李馨,夏俊杰. 胰腺癌梗阻性黄疸患者经皮穿刺胆管引流术后发生胰腺炎的危险因素分析. 实用癌症杂志. 2023(08): 1321-1324 . 百度学术
6. 杨立新,刘茜,周晶晶,唐亚丹,傅鹏,戴峰,白淑芬. 不同方法PTCD应用于梗阻性黄疸治疗中的体会. 现代医用影像学. 2023(12): 2229-2231+2235 . 百度学术
7. 华建军. 超声引导下经皮肝穿刺胆管引流术治疗对阻塞性黄疸病人胆红素水平与肝功能的影响研究. 贵州医药. 2022(02): 226-227 . 百度学术
8. 黄道琼,沈小叶,刘骏,刘月娥,陈瑜. 回授法在经皮肝穿刺胆管引流术后的应用. 介入放射学杂志. 2022(03): 294-297 . 百度学术
9. 彭赵宏,张德志,施万印,赵本胜,熊壮,汪名权,宋文,陶龙香,刘斌,张帅,程翔. ~(125)I粒子支架治疗恶性梗阻性黄疸支架通畅时间的影响因素分析. 安徽医科大学学报. 2022(04): 645-649 . 百度学术
10. 王玮,陈熙,罗丹,李启祥,尹合坤. 不同姑息性引流术对低位恶性梗阻性黄疸的近远期疗效及安全性分析. 当代医学. 2022(19): 39-42 . 百度学术
11. 买买提·瓦司力,高旭升,司俊杰,徐峰. 经皮肝穿引流和支架植入在恶性梗阻性黄疸患者治疗的疗效评价. 新疆医学. 2022(07): 770-772+809 . 百度学术
12. 王颖. 彩超引导经皮穿刺肝胆管引流术治疗梗阻性黄疸的临床研究. 中国医疗器械信息. 2022(15): 123-125 . 百度学术
13. 宋飞,向盈盈,车佳音,李红阳,徐文勇,魏凌潇,黄明. 胆道~(125)I粒子支架与金属裸支架治疗Bismuth Corlette Ⅲ型胆管癌合并梗阻性黄疸的临床对比. 昆明医科大学学报. 2022(11): 85-89 . 百度学术
14. 冉庆. ERCP联合PTCD胆总管支架置入胆管引流治疗恶性梗阻性黄疸的临床价值. 医学食疗与健康. 2021(04): 86-87 . 百度学术
15. 王锦程,余佩和,苏松,李波. 经内镜鼻胆管引流术与经内镜胆道支架置入术在低位恶性梗阻性黄疸术前胆道引流效果比较的Meta分析. 临床肝胆病杂志. 2021(04): 863-867 . 本站查看
16. 马博,周军,周京涛,李建刚,王俊. 胆道支架植入治疗恶性梗阻性黄疸术后并发症的发生因素分析. 现代生物医学进展. 2021(07): 1283-1286 . 百度学术
17. 张建松,侯森,崔虎啸. 超声引导下经皮肝穿刺胆道引流联合胆管复合支架置入术治疗晚期肝外胆管癌的效果. 癌症进展. 2021(09): 931-934 . 百度学术
18. 张华安,周晓芳,蒋易君,张淏嘉. NRS-2002联合炎症反应标志物预测恶性梗阻性黄疸患者预后的Nomogram模型构建. 山东医药. 2021(16): 35-40 . 百度学术
19. 石书伟,王劲. 经皮肝穿刺胆道引流联合金属支架植入术对恶性梗阻性黄疸的影响. 黑龙江医学. 2021(15): 1608-1609 . 百度学术
20. 宋英茜,陶冶. 梗阻性黄疸经皮肝穿刺胆道引流术后胆道感染的病原菌特点及其危险因素分析. 中国实用乡村医生杂志. 2021(02): 33-36 . 百度学术
21. 张志强,韩涛,崔钢,王奕,蔡恒烈,廖骞. 右肝管入路单通道横跨左右肝管引流治疗汇管区恶性梗阻性黄疸的临床研究. 中国普通外科杂志. 2021(12): 1503-1508 . 百度学术
22. 傅建英. 内镜介入治疗急性梗阻性黄疸的疗效及对患者炎症因子的影响. 中外医疗. 2021(33): 57-60 . 百度学术
23. 李蔚,王锡斌,崔卫东,杨青,刘会苗,杨金雨,王锡斌. 超声引导下经皮经肝胆管穿刺引流术治疗急性梗阻性化脓性胆管炎患者疗效分析. 实用肝脏病杂志. 2020(03): 447-450 . 百度学术
24. 李磊. 胆道支架联合经皮肝穿刺胆管引流术对晚期恶性梗阻性黄疸的临床应用价值. 名医. 2020(08): 85-86 . 百度学术
25. 张蓓,答秀维,张乐. 经皮肝穿刺胆道外引流治疗恶性梗阻性黄疸疗效及对患者细胞免疫功能、血清直接胆红素、超敏C反应蛋白水平的影响. 陕西医学杂志. 2020(10): 1249-1252 . 百度学术
26. 朱超,刘会春,胡小四,庞青,陈邦邦,李传涛. 胆道双支架联合~(125)I粒子腔内照射治疗恶性肝门部胆道梗阻的疗效分析. 介入放射学杂志. 2020(11): 1100-1104 . 百度学术
27. 姜磊,都晓英,孙医学,张大坤,周凯,徐建中,陈芳芳. PTBS术治疗恶性梗阻性黄疸的临床价值及预后因素分析. 蚌埠医学院学报. 2019(09): 1202-1205+1209 . 百度学术
28. 江新华. 64层螺旋CT3D成像与MRCP成像技术对胆道梗阻性疾病的诊断价值. 江西医药. 2019(11): 1336-1340 . 百度学术
29. 吴子鑫,吴申伟. 经皮肝穿刺胆道支架植入治疗对恶性梗阻性黄疸患者肝功能指标、炎症指标的影响. 齐齐哈尔医学院学报. 2019(24): 3098-3099 . 百度学术
30. 武飞. 经皮肝穿刺胆管引流术与Roux-en-Y胆肠吻合术治疗恶性梗阻性黄疸患者的对比研究. 中国药物与临床. 2019(23): 4098-4100 . 百度学术
其他类型引用(4)
-

计量
- 文章访问数: 1991
- HTML全文浏览量: 53
- PDF下载量: 326
- 被引次数: 34